The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Annabel Samimy - Stifel, Nicolaus & Company Inc - Analyst
: Great progress on operations. I want to know a little bit more about the CYTOGAM study and how this differs from the clinical data that's already
been -- that you've been using for clinical education so far, what this adds to the package? And I guess maybe you can sort of talk about the
population that does have this late onset CMV. Do you now have enough information to cover the totality of the transplant population with the
prior, I guess, studies that were conducted.
Question: Annabel Samimy - Stifel, Nicolaus & Company Inc - Analyst
: Okay. Great. That was helpful color. Then I guess I'm also curious about ATD, where you are with enrollment. Clearly, there's a lot -- there's an
increasing number of programs right now that are under development aside from gene therapy, there's some RNA editing options as well.
So how is that impacting your enrollment? And are you still -- I mean, I know you're on target for the interim study or interim analysis. How is the
enrollment completion time line looking and top line data?
Question: James Sidoti - Sidoti & Company LLC - Analyst
: Your distribution business in the last two quarters has really shot up. I think it was 80% growth in the second quarter, 60% growth this quarter. I
assume that's because of the addition of some of the new products to that business. Are these stocking orders? Or are these actual usage? Are
these the kind of numbers we should expect going forward?
Question: James Sidoti - Sidoti & Company LLC - Analyst
: And with the plasma collection centers in Texas, I assume you're collecting some specialty plasma now. Can you just give us a sense how much
you're collecting relative to what you require? Are you collecting the bulk of what you need now for your proprietary products? And when do you
think that -- or if not now, when do you think you'll be collecting enough plasma in Texas to supply your proprietary products?
Question: James Sidoti - Sidoti & Company LLC - Analyst
: Okay. And then last question for me. I know you said you plan to release some interim data from the clinical trial for the AATD treatment sometime
I would assume in December. How will you do that? Will it be a press release?
Will you have a conference call? How are you going to let the street know how that trial is going?
Question: Brian Ritchie - LifeSci Advisors, LLC - Analyst
: First question, so can you talk about the performance of CYTOGAM to date this year, Amir? And related to that, what are the significant growth
Question: Brian Ritchie - LifeSci Advisors, LLC - Analyst
: Thanks, Amir. With respect to GLASSIA royalties, now that those have declined to 6%, can you elaborate on where they'll go next year?
Question: Brian Ritchie - LifeSci Advisors, LLC - Analyst
: Thanks, Amir. Final question. Maybe you can comment on your current BD activities and seemingly lengthy time line to execute a transaction.
Question: Brian Ritchie - LifeSci Advisors, LLC - Analyst
: Thanks, Amir. I'll let you give your closing remarks now.
| 
